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Abstract
Background: Clozapine is the only licensed medication for treatment-resistant schizophrenia. The metabolism of
clozapine is affected by multiple pharmacokinetic interactions, so the co-administration of adjunct medications can
have a significant clinical effect. The anti- tuberculosis medication rifampicin is a potent inducer of the cytochrome
P450 system and therefore can cause a reduction in the plasma concentration of clozapine. There is limited clinical
evidence regarding co-administration of these medications; in particular there is a lack of data regarding the effect
on plasma clozapine levels, which is the key factor determining clinical efficacy. This is clinically relevant given
evidence of an increased risk of tuberculosis in patients with schizophrenia.
Case Presentation: We present a case of a 28 year old British man with a diagnosis of schizoaffective disorder who
presented with persistent psychotic symptoms. He developed a systemic inflammatory condition, diagnosed as
tuberculosis, and was commenced on a six month course of treatment that included rifampicin. This case presents
comprehensive data to illustrate the effect on clozapine plasma levels of a complete course of tuberculosis therapy.
Conclusion: This case report provides guidance to clinicians in managing drug interactions between clozapine and
rifampicin to enable safe and effective treatment. The co-administration of these medications is likely to increase as
the existing underuse of clozapine is recognised whilst the incidence of tuberculosis increases.
Keywords: Clozapine, Rifampicin, Schizophrenia, Schizoaffective disorder, Tuberculosis
Background
Clozapine is the only drug treatment licensed for use in
treatment-resistant schizophrenia [1]. The UK National
Institute for Health and Care Excellence recommends that
clozapine should be offered to people with schizophrenia
whose illness has not sufficiently responded to treatment,
despite the sequential use of adequate doses of two differ-
ent antipsychotic drugs [2], at least one of which should
be a non-clozapine second-generation antipsychotic [3].
Despite clear guidance in the UK, there is widespread
evidence that clozapine is underused [4, 5]. While rela-
tively few first onset patients with schizophrenia fail to
show a positive response to their first two antipsychotics
[6], later in the illness up to 30 % of patients fail to show
an adequate response, of whom 30–60 % would respond
to clozapine if offered [7]. The main reasons for not pre-
scribing clozapine may include clinician and patient con-
cern about the essential regular blood tests and potential
side effects [8]. Approximately 0.8 % of patients who take
clozapine will develop agranulocytosis [3, 9]. Mandatory
blood monitoring protocols provide timely identification
of any significant haematological abnormalities. The most
common adverse effects of clozapine are increased
sedation, hypersalivation, constipation, weight gain,
tachycardia, hypotension and seizures, but there are
clear management strategies for these [10]. Unlike the
risk of agranulocytosis, some of these side effects, such
as sedation and seizures, are known to be plasma-level
dependent.
The key variable determining the ultimate efficacy of
clozapine and the severity of some adverse effects is the
plasma concentration, which is determined by two main
factors: the dose of clozapine taken by the patient, and
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the speed of its metabolism. There is a high inter-patient
variability in the relationship between clozapine dose
and serum level, reflecting variability in its metabolism
between patients [11, 12]. Measurement of serum levels
is therefore important to ensure both an optimal thera-
peutic level and to minimise the risk of toxic side effects.
Most studies of patients with treatment-resistant schizo-
phrenia indicate that the threshold for response is in the
range 0.35–0.42 mg/L [13], although others suggest a
higher upper limit of 0.50 mg/L [14]. Tolerability can be
improved by employing a gradual initial titration regi-
men, with subsequent dose changes made on the basis
of adverse side effects, effectiveness and plasma levels.
Clozapine undergoes complex hepatic metabolism in-
volving multiple cytochrome P450 (CYP) isoforms, the
enzyme variants that catalyse biotransformation reac-
tions (Fig. 1). It is primarily metabolised by the CYP1A2
isoform, but CYP3A4 and to a lesser extent CYP2C9,
CYP2C19 and CYP2D6 are also involved [15]. Conse-
quently, clozapine is involved in significant pharmacoki-
netic interactions when co-administered with other
drugs. CYP1A2 isoforms are inhibited by some antide-
pressants (including fluoxetine and fluvoxamine) and
caffeine, resulting in increased clozapine plasma concen-
trations [16]. Conversely, CYP1A2 isoforms may be in-
duced by some antibiotics (erythyromycin) and cigarette
smoke (through the effect of aromatic hydrocarbons),
which will decrease clozapine plasma concentrations
[17, 18]. The antimycobacterial agent rifampicin is an in-
ducer of CYP1A2 and CYP3A4 [15, 19]; adjunct treat-
ment with rifampicin would be expected to decrease
serum concentrations of clozapine. The consistency of
CYP-mediated drug interactions with clozapine is not al-
ways easy to predict [20].
Whilst tuberculosis (TB) has been considered to be
largely restricted to lower income parts of the world, in-
creased global travelling has caused a resurgence of this
illness in higher income countries, particularly in certain
urban centres. The incidence of TB is higher in people
with schizophrenia than in the general population [21],
and there are common risk factors for the development
of severe mental illness and the development of multi-
drug resistant TB (homelessness, substance abuse and
imprisonment) [22].
First-line medication for TB is a quadruple therapy
regimen of rifampicin, isoniazid, pyrazinamide and eth-
ambutol for two months, followed by a four month con-
tinuation phase of rifampicin and isoniazid [1]. The
literature on the interaction between rifampicin and clo-
zapine is limited to three case reports; the first reports a
halving of haloperidol plasma concentrations, and in-
creased clearance of diazepam by 300 % and nitrazepam
by 83 %, upon commencing rifampicin [23]. The second
describes a patient stabilised on clozapine who experi-
enced a significant decrease in his clozapine plasma con-
centration when rifampicin was added to therapy, with
an exacerbation of psychotic symptoms [24]. The de-
crease in clozapine concentration was seen 2–3 weeks
after the initiation of rifampicin and levels rose 3 days
after rifampicin treatment was discontinued, although
the concomitant substitution with the enzyme inhibitor
ciprofloxacin may also have contributed to this effect. A
third report describes a notable deterioration in psych-
otic symptoms in a patient with schizophrenia during
Fig. 1 The main clozapine metabolic pathways and pharmacokinetic interactions
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the six months of rifampicin therapy [25]; no data on
clozapine levels were available, but the deterioration in
symptoms persisted despite an increase in the dose of
clozapine from 300 mg to 550 mg/day.
Whilst literature describing the interaction between
clozapine and rifampicin is limited to the three case re-
ports described above, many more reports demonstrate
the effect of adding rifampicin to other psychotropics.
Given than rifampicin (as stated above) induces CYP1A2
and 3A4, a reduction in plasma concentrations of medi-
cations that are metabolised by these enzymes should be
expected. As well as clozapine, the antipsychotic olanza-
pine is also a substrate for CYP1A2 (and, like clozapine,
this isoform is the predominant metabolic pathway for
the drug) [2]. Interestingly, reports of reduction in olan-
zapine plasma concentrations due to co-administration
of rifampicin are absent from the literature – perhaps
because measurement of olanzapine levels is not usually
considered part of routine clinical practice.
Many different psychotropics are metabolised by CYP3-
A4, including aripiprazole, methadone, mirtazapine, clo-
nazepam, quetiapine and zopiclone. Studies in healthy
subjects clearly establish the pharmacokinetic interaction
between rifampicin and many of the benzodiazepines and
non-benzodiazepine hypnotics [26–28], the antidepressant
bupropion [29] and the anxiolytic buspirone [30]. Case re-
ports describe reductions in plasma concentrations of psy-
chotropics when combined with rifampicin even where
the rifampicin inhibited CYP enzyme might not be con-
sidered as the main metabolic pathway for the drug – this
is the case for amitriptyline [31], sertraline [32], citalo-
pram [33] and haloperidol [34]. Interactions with other
psychotropics, including quetiapine and aripiprazole, are
not described in the literature but are limited to suppos-
ition based on the metabolism of the drug.
Interactions between rifampicin and psychotropics are
not limited to mechanisms involving CYP enzymes. A
study in healthy subjects [35] and a case report [36] de-
scribe reductions in lamotrigine plasma concentrations
caused by rifampicin, possibly due to increased lamotrigine
glucuronidation via glucuronyltransferases. CYP3A4 is a
minor metabolic pathway for the antipsychotic risperidone,
but two studies describe marked decreases in plasma con-
centrations when rifampicin is co-administered [37, 38].
The authors suggest the possible role of P-glycoprotein in
this interaction.
There is little guidance available to aid clinicians faced
with patients with schizophrenia on clozapine treatment,
who are also initiating concurrent treatment for TB.
This is an increasing issue for deprived urban areas in
cities with large migrant populations, and for those pa-
tients who are immunocompromised or abusing illicit
drugs [22, 39]. Here we discuss the changes in the
plasma concentration of clozapine using an illustrative
case of a patient stabilised on clozapine who commenced
a course of TB treatment which included rifampicin.
Case Presentation
The National Psychosis Service at the Maudsley Hospital
(South London and Maudsley NHS Foundation Trust,
(SLaM)) is a tertiary referral centre for patients with
complex treatment- resistant psychotic illnesses, often
with significant co-morbid physical health conditions
[40]. Clozapine is therefore frequently prescribed in
combination with a range of other physical health medi-
cations. The recommended therapeutic range for cloza-
pine plasma levels at SLaM is 0.35 to 0.50 mg/L
although occasionally higher plasma levels may be tar-
geted with adequate seizure prophylaxis.
Mr X is a 28 year old British man of African heritage
who has been known to mental health services since the
age of 18, with a diagnosis of schizoaffective disorder.
He had spent over 4 years as an inpatient in hospital,
spread over 9 admissions, and had been an inpatient for
two years before being transferred to the National
Psychosis Service. He presented with manic and depres-
sive phases to his illness, both of which had been associ-
ated with auditory and visual hallucinations, bizarre
delusional beliefs and catatonia.
During the course of his illness he has been treated
with both first and second generation antipsychotics for
over 6 weeks duration at maximum recommended doses
with a limited response. He had previously shown some
positive response to clozapine during an earlier period
of illness, but this was stopped due to concerns about
developing diabetes. He was recommenced on clozapine
treatment soon after admission to the National Psychosis
Unit. His other psychotropic medication included fluox-
etine for depressive symptoms and lamotrigine as both a
mood stabiliser and for seizure prophylaxis.
Over the last two years he had been experiencing a
chronic systemic inflammatory condition. He was ini-
tially transferred to a general hospital after developing
signs of abdominal sepsis and blood tests that revealed
microcytic anaemia and a significant inflammatory re-
sponse. Despite an extensive range of investigations, in-
cluding blood and sputum samples and an inconclusive
lymph node biopsy a definitive cause for his presentation
was not identified. Various specialists concluded that he
should be treated empirically for abdominal TB. A six
month course of rifampicin and isoniazid was commenced
together with pyrazinamide and moxifloxacin for the first
two of those months.
In the 5 months prior to commencing TB treatment,
his clozapine levels were generally in the range 0.24 to
0.36 mg/L with the highest level being reported as
0.65 mg/L (Fig. 2). The initial clozapine dose of 300 mg/
day was increased to 400 mg/day once his fluoxetine
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was stopped, in anticipation of a potential drop in the
clozapine level following the loss of enzyme inhibition.
On commencing TB treatment and in anticipation of
the likely impact of enzyme induction; the clozapine
dose was increased to 500 mg/day with further progres-
sive increases over subsequent weeks. Only when the
clozapine dose reached 800 mg/day after 2 months of
TB treatment did clozapine levels reach the therapeutic
range. This was maintained for only 3 weeks before the
level again dropped. Despite increasing the clozapine
dose to 1000 mg/day, clozapine levels did not reach the
therapeutic range for the remainder of the TB treatment.
Unfortunately this period coincided with Mr. X being
very unwell with increased levels of psychotic symptoms
on the catatonic spectrum including mutism, stereoty-
pies and agitation.
On stopping TB treatment, the clozapine dose was pro-
spectively halved by down-titrating at a rate of 50 mg/day
over 10 days. The clozapine plasma level remained rela-
tively steady and subsequent increases in dose to 500 mg/
day then 550 mg/day finally led to reaching a clozapine
plasma level within the therapeutic range. The degree of
psychotic symptoms improved including increased spon-
taneous speech, reduced distraction, reduced stereotypies
and increased goal directed activity.
Discussion
This case highlights the difficulty in achieving a thera-
peutic level of clozapine when a powerful enzyme in-
ducer such as rifampicin is used. Even when using a
clozapine dose above the licensed maximum, the level
remained sub-therapeutic. A limitation of this report is
the absence of formal outcome measures but clinical
observations of presentation reflected sub-therapeutic
levels. Although confirmed compliance with medication
is often difficult to assess in patients with psychosis,
there were no concerns about compliance with medica-
tion at this time. The patient is a non-smoker, not noted
to have significant intake of caffeine and no other medi-
cations known to interact with the clozapine metabolic
pathways were changed during the period. His renal and
liver function tests remained stable throughout the treat-
ment period. All clozapine plasma level measurements
were taken at consistent times (trough levels). It is
possible that the presence of abdominal TB affected the
absorption of clozapine from the gastrointestinal tract,
although a comparison of absorption of isoniazid and
rifampicin in patients with abdominal TB and pulmonary
TB showed no differences in drug absorption for patients
with abdominal TB, at least for these two drugs [41].
Given the naturalistic trajectory of drug treatment in
this patient, and the clinical imperative to avoid both clo-
zapine toxicity and sub-therapeutic levels, medication
changes were made to anticipate likely effects on cloza-
pine levels. This optimises safety but complicates inter-
pretation of drug levels associated directly with any single
medication change. On stopping the pyrazinamide and
moxifloxacin component of TB treatment after 2 months
there was a 3 week period of raised clozapine levels. This
was the only time during the total 6 months of TB treat-
ment that levels were above the sub-therapeutic threshold.
There is no literature to suggest that pyrazinamide or
moxifloxacin interact with clozapine metabolism so the
cause for this remains unclear. Isoniazid is a CYP1A2
Fig. 2 Clozapine plasma levels and the effect of medication changes
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inhibitor, and is therefore expected to increase clozapine
plasma concentrations [42]. It is likely that this effect was
counteracted, at least in part, by rifampicin in our patient.
As both drugs were initiated together, it is not possible to
elucidate the extent to which isoniazid may have amelio-
rated the effect of rifampicin on clozapine plasma levels.
It is difficult to estimate precisely the time taken for
medication changes to affect enzyme induction and de-
induction and hence clozapine levels. However, 12 days
after starting rifampicin treatment, the clozapine plasma
level of 0.19 mg/L was lower than any preceding level
since starting clozapine, despite having increased the
dose by 100 mg/day in anticipation of the induction ef-
fect. This was the first level checked after starting rifam-
picin, and it is possible that enzyme induction was in
fact quicker than 12 days and certainly faster than the
2–3 weeks reported by Joos et al. [24] Regarding de-
induction after stopping rifampicin, the first available
level was after 16 days and at 0.35 mg/L was at the lower
limit of the therapeutic range. It was not until 4 weeks
later that the level was consistently in the therapeutic
range. The fact that in the interests of patient safety the
clozapine dose was down-titrated immediately on stop-
ping rifampicin makes it more difficult to interpret the
effect of enzyme de-induction of clozapine.
Rifampicin is also known to affect the pharmacokinetics
of lamotrigine [35]. Lamotrigine plasma levels decreased
on addition of rifampicin for this patient, necessitating
dose increases to maintain plasma levels within the thera-
peutic range. It is possible that this reduction in plasma
levels contributed to the deterioration in mental state, but
we consider it unlikely that this was solely responsible.
Although the proportion of TB cases reported in the
UK to be resistant to at least one first line antibiotic ap-
pears to be reducing, risk factors for resistance include
homelessness, substance abuse and imprisonment [22].
It is possible then that psychiatrists may be more likely
to see such cases. Where resistance to the standard first-
line drugs exists (isoniazid, rifampicin, pyrazinamide,
ethambutol), medications such as streptomycin, amika-
cin, capreomycin, cycloserine, azithromycin, clarithro-
mycin, moxifloxacin and protionamide may be used
instead [1]. Considering the pharmacodynamic proper-
ties of these drugs and the available literature, interac-
tions with clozapine are unlikely. Prescribers should be
aware however that increases in clozapine concentration
have been reported in combination with erythromycin,
and that both clozapine and clarithromycin may prolong
the QTc interval. It is also worth noting that bacterial in-
fections have been reported to increase clozapine con-
centrations independently of any drug effects [43, 44]
and so it may be prudent to measure clozapine plasma
levels in the presence of concurrent infections, even in
the absence of reported pharmacological interactions.
Conclusions
In summary, it is appropriate to increase the dose of clo-
zapine on commencing an enzyme inducing medication
such as rifampicin. The induction effect can be seen
within a matter of days and it is notable that even doub-
ling the clozapine dose may not result in therapeutic
plasma levels. . On stopping rifampicin, the clozapine dose
should be reduced. As the risks of clozapine toxicity
should be deemed potentially more harmful than a sub-
therapeutic level, down-titration may be implemented
relatively quickly. Prescribers should be aware of the sig-
nificant inter-patient variability in clozapine metabolism.
We suggest the following key principles be used to ensure
effective and safe treatment of a psychotic illness with clo-
zapine when co-administering a course of TB therapy:
Take clozapine plasma levels before commencing TB
therapy to establish the ‘target’ plasma level for the indi-
vidual patient.
Monitor clozapine levels weekly during TB therapy to
determine the individual patient’s pharmacokinetic re-
sponse to the drug. Alter the clozapine dose accordingly.
Twice weekly plasma level monitoring in the initial
weeks may be warranted.
It may be necessary to exceed the licensed maximum
dose of clozapine to attain a therapeutic plasma level. It
is good practice to involve a second opinion from a col-
league if such a treatment plan is to be implemented. As
such a strategy will be unlicensed, consent should be
sought if possible from the patient, and all decisions
carefully documented.
Use information from the up-titration stage to inform
the speed and extent of the down-titration stage, aiming
for the pre-treatment dose of clozapine at cessation of
TB therapy.
Down-titration of clozapine may be carried out rela-
tively rapidly (over 7 – 10 days), acknowledging the risks
of high clozapine plasma levels. Seizure prophylaxis with
an appropriate antiepileptic should be considered if
plasma clozapine levels exceed 0.5 mg/L.
Consent
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acity to consent to this publication. Written informed
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the Editor of this journal.
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